# NIH Reporter #5P01CA163205-14

Project 4: Awakening immune responses to GBM by enhancing immune cell trafficking and activation with oHSV armed with Cetuximab-CCL5 and anti-CD47 antibody payloads.

**Recipient:** BRIGHAM AND WOMEN'S HOSPITAL

**Award Amount:** $354,153.00
**Ceiling:** $354,153.00

**Awarded:** September 09, 2026

**Identifier:** 5P01CA163205-14

NIH/NCI awarded a project to develop oncolytic viruses to treat glioblastoma by enhancing immune cell trafficking and activation using oHSV armed with Cetuximab-CCL5 and anti-CD47 antibody payloads.

### Description

The project involves developing oncolytic viruses for glioblastoma treatment, including preclinical efficacy and safety studies, funded by the NIH/NCI under grant number 5P01CA163205-14. The project aims to enhance immune responses in the tumor microenvironment.

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11394542)